Antiallergic drug desloratadine as a selective antagonist of 5HT_2A receptor ameliorates pathology of Alzheimer's disease model mice by improving microglial dysfunction.

ABSTRACT: Alzheimer's disease (AD) is a progressively neurodegenerative disease characterized by cognitive deficits and alteration of personality and behavior. As yet, there is no efficient treatment for AD. 5HT_2A receptor (5HT_2A R) is a subtype of 5HT₂ receptor belonging to the serotonin receptor family, and its antagonists have been clinically used as antipsychotics to relieve psychopathy. Here, we discovered that clinically first-line antiallergic drug desloratadine (DLT) functioned as a selective antagonist of 5HT_2A R and efficiently ameliorated pathology of APP/PS1 mice. The underlying mechanism has been intensively investigated by assay against APP/PS1 mice with selective 5HT_2A R knockdown in the brain treated by adeno-associated virus (AA

SUBMITTER: Lu J 

PROVIDER: S-EPMC7811850 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature